acFibroMASH指数用于诊断纤维化型MASH并预测肝脏相关事件:一项国际多中心研究
该国际多中心研究基于3004例经活检证实的MASLD患者验证acMASH指数诊断MASH,并开发acFibroMASH指数识别纤维化型MASH;acFibroMASH识别纤维化型MASH的AUROC在推导队列为0.808、验证队列为0.800,预测5年肝脏相关事件风险优于FAST评分,acFibroMASH>0.39者肝脏相关事件风险高于<0.15者(校正HR 11.23)。
要点
- acMASH指数在汇总全球队列中诊断MASH的AUROC为0.802(95%CI 0.786-0.818)。
- acFibroMASH指数识别纤维化型MASH的AUROC在推导队列为0.808、验证队列为0.800。
- acFibroMASH>0.39者肝脏相关事件风险高于<0.15者(校正HR 11.23,95%CI 3.98-31.66)。
核心结论
- 该多种族研究验证acMASH指数是识别MASH的可靠无创检测方法。
- 新提出的acFibroMASH指数是识别纤维化型MASH并预测肝脏相关事件风险的可靠检测方法。
研究设计与样本
- 研究分析了来自29个中国队列和9个国际队列共3004例经活检证实的MASLD患者数据,以验证acMASH指数并开发acFibroMASH指数。
- 研究另利用一个多种族MASLD患者独立外部队列(9034例)分析acFibroMASH指数与肝脏相关事件风险的关联。
主要发现
- 在汇总全球队列中,acMASH指数识别MASH的AUROC为0.802(95%CI 0.786-0.818)。
- acFibroMASH指数(包含acMASH指数加肝脏硬度测量)在推导队列识别纤维化型MASH的AUROC为0.808,在验证队列为0.800。
- acFibroMASH指数预测5年肝脏相关事件风险的AUROC为0.835(95%CI 0.786-0.882),优于FAST评分的0.750(95%CI 0.693-0.800;P<.01)。
- acFibroMASH>0.39的患者肝脏相关事件风险高于acFibroMASH<0.15者(校正风险比11.23,95%CI 3.98-31.66)。
关键数值与推荐
- acMASH指数包含血清肌酐和天冬氨酸氨基转移酶浓度。
- acFibroMASH指数包含acMASH指数加肝脏硬度测量。
- acFibroMASH>0.39与肝脏相关事件风险升高相关(校正HR 11.23,95%CI 3.98-31.66)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Metabolic dysfunction-associated steatohepatitis (MASH) and fibrotic MASH are significant health challenges. This multi-national study aimed to validate the acMASH index (including serum creatinine and aspartate aminotransferase concentrations) for MASH diagnosis and develop a new index (acFibroMASH) for non-invasively identifying fibrotic MASH and exploring its predictive value for liver-related events (LREs). METHODS: We analyzed data from 3004 individuals with biopsy-proven metabolic dysfunction-associated steatotic liver disease (MASLD) across 29 Chinese and 9 international cohorts to validate the acMASH index and develop the acFibroMASH index. Additionally, we utilized the independent external data from a multi-national cohort of 9034 patients with MASLD to examine associations between the acFibroMASH index and the risk of LREs. RESULTS: In the pooled global cohort, the acMASH index identified MASH with an area under the receiver operating characteristic curve (AUROC) of 0.802 (95% confidence interval [CI], 0.786-0.818). The acFibroMASH index (including the acMASH index plus liver stiffness measurement) accurately identified fibrotic MASH with an AUROC of 0.808 in the derivation cohort and 0.800 in the validation cohort. Notably, the AUROC for the acFibroMASH index was 0.835 (95% CI, 0.786-0.882), superior to that of the FAST score at 0.750 (95% CI, 0.693-0.800; P < .01) in predicting the 5-year risk of LREs. Patients with acFibroMASH >0.39 had a higher risk of LREs than those with acFibroMASH <0.15 (adjusted hazard ratio, 11.23; 95% CI, 3.98-31.66). CONCLUSIONS: This multi-ethnic study validates the acMASH index as a reliable, noninvasive test for identifying MASH. The newly proposed acFibroMASH index is a reliable test for identifying fibrotic MASH and predicting the risk of LREs.
引用
- Feng G, Mózes FE, Ji D, et al. acFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter Study. Clin Gastroenterol Hepatol. 2024. PMID: 39362618. doi:10.1016/j.cgh.2024.07.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。